Diabetic Kidney Disease
Conditions We Treat
Diabetic Kidney Disease
Diabetic kidney disease is the leading cause of kidney failure in the United States. It is also one of the most preventable — with early, aggressive nephrology management.
What is diabetic kidney disease?
Diabetic kidney disease (DKD), also called diabetic nephropathy, is kidney damage caused by diabetes. It develops in approximately 40% of people with diabetes and is the single most common cause of end-stage renal disease in the United States, accounting for roughly 44% of all new dialysis cases each year.
DKD develops gradually over years. Chronically elevated blood sugar damages the small blood vessels in the kidneys' filtering units (glomeruli), causing them to leak protein into the urine — a condition called proteinuria or albuminuria. As damage accumulates, filtration capacity declines, and kidney function falls. The process is often silent until significant damage has already occurred.
The good news is that DKD progression can be substantially slowed — and in some cases halted — with aggressive management of blood sugar, blood pressure, and the underlying metabolic drivers of kidney injury. New drug classes, particularly SGLT2 inhibitors and GLP-1 receptor agonists, have transformed the treatment landscape in the past decade.
Key Statistics
How we approach diabetic kidney disease
SGLT2 inhibitor therapy
Drugs like empagliflozin, dapagliflozin, and canagliflozin have demonstrated 30–40% reductions in kidney failure risk in patients with DKD. We initiate and manage these agents in appropriate patients.
Blood pressure control to target
We target blood pressure below 130/80 mmHg using ACE inhibitors or ARBs — which reduce proteinuria and slow kidney disease progression independent of their blood pressure effect.
Proteinuria monitoring and reduction
Urine albumin-to-creatinine ratio is the most sensitive early marker of DKD. We track it at every visit and adjust treatment to minimize protein leak.
Metabolic optimization
Glycemic control, weight management, and lipid management all affect kidney outcomes. We coordinate with endocrinology and primary care to optimize the full metabolic picture.
Frequently asked questions
What is diabetic kidney disease?
Diabetic kidney disease (DKD) is kidney damage caused by diabetes. It develops when chronically elevated blood sugar damages the small blood vessels in the kidneys' filtering units, causing them to leak protein and gradually lose function.
How do I know if I have diabetic kidney disease?
DKD is detected through urine and blood tests. A urine albumin-to-creatinine ratio above 30 mg/g indicates early kidney damage. An eGFR below 60 indicates reduced kidney function. Both tests should be performed annually in all patients with diabetes.
Can diabetic kidney disease be prevented?
Yes — with aggressive management of blood sugar and blood pressure, and the use of kidney-protective medications. The window for prevention is widest in the early stages, before significant damage has occurred.
What is the role of SGLT2 inhibitors in DKD?
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) are now first-line therapy for DKD in patients with type 2 diabetes. They reduce the risk of kidney failure by approximately 34% and also reduce cardiovascular events.
Related conditions
Diabetic kidney disease is manageable — with the right specialist.
Our nephrologists specialize in DKD management and SGLT2 inhibitor therapy. Accepting new patients in Newport Beach.